Iowa City, IANCT07541781Now EnrollingIRB Ready

Glioma Clinical Trial in Iowa City, IA

Access cutting-edge glioma treatment through this phase 1 clinical trial at a research site in Iowa City. Study-provided care at no cost to qualified participants.

Sponsored by Kailin Yang, MD, PhD

Quick Self-Assessment

See if you qualify for this Iowa City location

Preparing your pre-screening questions…

Expert Care in Iowa City

Access glioma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related glioma treatment provided free

Apply for This Iowa City Location

Check if you qualify for this glioma clinical trial in Iowa City, IA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Iowa City

    Convenient for IA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Iowa City site if eligible
  4. 4Begin participation

About This Glioma Study in Iowa City

Sitagliptin, when combined with standard-of-care drug bevacizumab, is being tested to 1) find out if it is effective at treating gliomas that have returned or progressed after treatment, and 2) find out what the highest dose of sitagliptin is appropriate to give when combined with bevacizumab.

Sponsor: Kailin Yang, MD, PhD

Who Can Participate

Inclusion Criteria

Subjects must have histologically or cytologically confirmed WHO grade 4 glioma for which disease recurrence/progression after first line therapy is diagnosed by the treating physician.
Subjects must not have received sitagliptin or bevacizumab for this disease.
Age \>18 years
Performance status: ECOG performance status 0-2
Subjects must have adequate organ function and laboratory parameters within 21 days of study entry as defined below:
Hemoglobin ≥ 9 g/dl
Absolute neutrophil count ≥ 1,500/mcL
Platelet count ≥ 100,000/mcL
Total bilirubin \< 1.5 x institutional upper limit of normal (ULN)
AST (SGOT) ≤ 3 X institutional ULN
ALT (SGPT) ≤ 3 X institutional ULN
Calculated creatinine clearance \> 50 mL/min
Urine protein screened by urine analysis for urine protein creatinine (UPC) ratio. For UPC ratio \> 0.5, 24-hour urine protein must be obtained and must be \< 1000 mg.
Patients on full-dose anticoagulants (e.g., warfarin or LMW heparin) must meet both of the following criteria:
No active bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices)
In-range INR (between 2 and 3) on a stable dose of oral anticoagulant or on a stable dose of low molecular weight heparin
Subjects must have the ability to understand and the willingness to sign a written informed consent document.
Women of childbearing potential, defined as any female who has experienced menarche and has not undergone surgical sterilization (e.g., hysterectomy, bilateral oophorectomy) and is not postmenopausal (≥12 months of spontaneous amenorrhea without an alternative medical cause), must have a negative pregnancy test within 7 days prior to treatment start. Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and through 30 days after the last dose of study drug. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and through 30 days after the last dose of study drug.
Subjects must be able to swallow whole tablets.
Participants must have controlled blood pressure, defined as systolic blood pressure ≤ 160 mg Hg or diastolic pressure ≤ 100 mg Hg, with or without antihypertensive therapy
Electrocardiogram without evidence of acute cardiac ischemia within 14 days prior study treatment
Subjects must have the following minimum intervals from prior treatments until planned treatment initiation of Cycle 1 Day 1:
surgery - 4 weeks
nitrosoureas - 6 weeks
cytotoxic chemotherapy - standard intervals depending on the most recent regimen. i.e., for temozolomide 5 of 28, 23 days after most recent temozolomide; for temozolomide 21 of 28 days, 7 days after most recent dose; etoposide 14 of 21 days, 7 days after last dose.
For drugs not listed, the research nurse, treating investigator, and principal investigator will determine the appropriate interval.
Investigational therapy or non-cytotoxic GBM related therapy - 2 weeks
Subject is not deemed as a surgical candidate. Pilot Phase
Subjects must have histologically or cytologically confirmed WHO grade 4 glioma for which disease recurrence/progression after first line therapy is diagnosed by the treating physician.
Subjects must not have received sitagliptin or bevacizumab for this disease.
Age \>18 years
Performance status: ECOG performance status 0-2
Subjects must have adequate organ function and laboratory parameters within 21 days of study entry as defined below:
Hemoglobin ≥ 9 g/dl
Absolute neutrophil count ≥ 1,500/mcL
Platelet count ≥ 100,000/mcL
Total bilirubin \< 1.5 x institutional upper limit of normal (ULN)
AST (SGOT) ≤ 3 X institutional ULN Version date: 30March2026 Page 16
ALT (SGPT) ≤ 3 X institutional ULN
Calculated creatinine clearance \> 50 mL/min
Urine protein screened by urine analysis for urine protein creatinine (UPC) ratio. For UPC ratio \> 0.5, 24-hour urine protein must be obtained and must be \< 1000 mg.
Patients on full-dose anticoagulants (e.g., warfarin or LMW heparin) must meet both of the following criteria:
No active bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices)
In-range INR (between 2 and 3) on a stable dose of oral anticoagulant or on a stable dose of low molecular weight heparin
Subjects must have the ability to understand and the willingness to sign a written informed consent document.
Women of childbearing potential, defined as any female who has experienced menarche and has not undergone surgical sterilization (e.g., hysterectomy, bilateral oophorectomy) and is not postmenopausal (≥12 months of spontaneous amenorrhea without an alternative medical cause), must have a negative pregnancy test within 7 days of treatment start. Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and through 30 days after the last dose of study drug. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and through 30 days after the last dose of study drug.
Subjects must be able to swallow whole tablets.
Subjects must have controlled blood pressure, defined as systolic blood pressure ≤ 160 mg Hg or diastolic pressure ≤ 100 mg Hg, with or without antihypertensive therapy
Electrocardiogram without evidence of acute cardiac ischemia within 14 days prior to treatment start
Subjects must have the following minimum intervals from prior treatments until planned treatment initiation of Cycle 1Day1:
surgery - 4 weeks
nitrosoureas - 6 weeks
cytotoxic chemotherapy - standard intervals depending on the most recent regimen. i.e., for temozolomide 5 of 28, 23 days after most recent temozolomide; for temozolomide 21 of 28 days, 7 days after most recent dose; etoposide 14 of 21 days, 7 days after last dose.
For drugs not listed, the research nurse, treating investigator, and principal investigator will determine the appropriate interval.
Investigational therapy or GBM related non-cytotoxic therapy - 2 weeks
For bevacizumab (if for a different cancer) - 4 weeks from the expected date of protocol surgery
Subject is deemed as a surgical candidate.

Exclusion Criteria

(for phase 1b and pilot phase)
Prior treatment toxicities not resolved to ≤ Grade 1 according to NCI CTCAE Version 5.0 except for alopecia and neuropathy.
Subjects receiving any other investigational agents.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to sitagliptin or bevacizumab.
Subjects with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
Known HIV-positive subjects on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with sitagliptin and/or bevacizumab. In addition, these subjects are at increased risk of lethal infections when treated with marrow suppressive therapy.
Other malignancy within the past 2 years with the exception of a) adequately treated basal cell carcinoma, squamous cell skin cancer, or thyroid cancer; b) carcinoma in situ of the cervix or vulva; c) prostate cancer of Gleason Score 6 or less with stable prostate specific antigen levels; or d) cancer considered cured by surgical resection or unlikely to impact survival during the duration of the study, such as localized transitional cell carcinoma of the bladder, or benign tumors of the adrenal or pancreas.
Significant chronic gastrointestinal disorder with diarrhea as a major symptom (e.g., Crohn's disease, malabsorption, or Grade ≥2 (National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events Version 5.0 \[CTCAE v.5.0\] diarrhea of any etiology at screening).
Known active infection with hepatitis B or hepatitis C virus.
Pregnant or breastfeeding.
Subjects who receive insulin or sulfonylurea for diabetes mellitus.
Subjects with history of type 1 diabetes, uncontrolled type 2 diabetes, hypoglycemia requiring medical intervention, or those who are deemed not suitable to receive sitagliptin at the discretion of the investigators.
Unable or unwilling to swallow tablets.
Evidence of significant medical illness, abnormal laboratory finding, or psychiatric illness/social situations that would, in the Investigator's judgment, make the patient inappropriate for this study.
Arterial ischemic event (e.g., unstable angina, myocardial infarction, stroke) within 6 months of study consent.
Subjects with history of hematologic bleeding disorder.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Iowa City?

Yes, this clinical trial (NCT07541781) has an active research site in Iowa City, IA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Glioma Treatment Options in Iowa City, IA

If you're searching for glioma treatment options in Iowa City, IA, this clinical trial (NCT07541781) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Iowa City research site is actively enrolling participants for this phase 1 clinical trial. You'll receive care from experienced glioma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all glioma clinical trials near you to find additional studies recruiting in your area.

More Brain Cancer Trials in Iowa City, IA

See all brain cancer clinical trials recruiting in Iowa City — not just this study.

Browse Brain Cancer Trials in Iowa City →

Browse More Trials by Condition

Brain Cancer TrialsAll Conditions →

Ready to Join in Iowa City?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Iowa City, IA